| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 272 | 323 | 853 | 564 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 154 | 189 | 627 | 445 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 118 | 133 | 226 | 118 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 40 % | 38 % | 25 % | 19 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 17 | 20 | 54 | 45 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 2 | 3 | 10 | 10 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 100 | 110 | 161 | 63 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 18 | 26 | 44 | 16 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 82 | 83 | 117 | 46 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.23 | 3.26 | 3.16 | 1.28 |
Cohance Lifesciences
Cohance Lifesciences
966.35
-24.35
(-2.46%)
Market Cap
37,900.90 Cr
EPS
10.52
PE Ratio
105.30
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
1,360.00
52 Week Low
856.30
PB Ratio
21.66
Debt to Equity
0.09
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
Company News
View All News
Jusmiral Holdings plans to sell up to 5.1% of its stake in Cohance Lifesciences through block deals. The offer is valued at ₹1,756 crore with a floor price of ₹900 per share, representing a 6.9% discount to the stock's last close. A 210-day lock-up period has been established for any additional share sales. Cohance Lifesciences is a Hyderabad-based Contract Development & Manufacturing Organisation serving international pharmaceutical, fine chemicals and biotech companies. The company changed its name from Suven Pharmaceuticals in May 2025. Cohance shares closed at ₹967.70, down 2.2%, and are trading 9.7% lower year-to-date, well below the 52-week high of ₹1,359.
Cohance Lifesciences' Andhra Pradesh API Facility Passes USFDA CGMP Inspection Without Observations
2 days ago
2 days agoCohance Lifesciences announced that its Active Pharmaceutical Ingredient (API) manufacturing facility in Andhra Pradesh successfully cleared a USFDA Current Good Manufacturing Practice (CGMP) inspection with zero observations. This regulatory clearance indicates the facility met all FDA manufacturing standards without any compliance issues identified during the inspection.
Cohance Lifesciences Limited completed a USFDA inspection at its API manufacturing facility in Jaggaiahpet, Andhra Pradesh. The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations. The audit focused on current Good Manufacturing Practices (cGMP) compliance at the company's API Unit-1 facility. The company stated its commitment to maintaining quality standards and regulatory compliance for manufacturing pharmaceutical products for global markets.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,620.20 | #1 3,86,412.90 | 33.89 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 49.41 | |
6,051.50 | 1,61,922.60 | 69.65 | 9,712.00 | 18.67 | 2,191 | 26.74 | 46.47 | |
1,559.60 | 1,25,921.60 | 23.36 | 28,409.50 | 7.12 | 5,291 | 9.88 | 51.03 | |
3,548.30 | 1,19,657.40 | 59.39 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.91 | |
1,311.40 | 1,09,362.20 | #1 19.26 | 33,741.20 | 16.73 | 5,725 | 1.26 | 60.11 | |
2,570.20 | 1,06,063.00 | 56.09 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 53.12 | |
1,033.80 | 1,04,094.90 | 22.34 | 23,511.00 | 18.55 | 4,615 | 2.60 | 62.88 | |
2,031.20 | 93,704.80 | 25.08 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 68.18 | |
5,472.50 | 65,796.60 | 28.79 | 13,458.30 | 3.70 | 2,216 | 21.39 | 70.33 | |
30,970.00 | 65,724.10 | 45.28 | 6,684.70 | 9.64 | 1,414 | 11.55 | 39.16 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-19.72 %
Net Income Growth
-26.99 %
Cash Flow Change
-25.11 %
ROE
-38.23 %
ROCE
-39.27 %
EBITDA Margin (Avg.)
-6.12 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 |
| Total Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 385 | 288 |
| Financing Activities | 26 | 7 | -76 | -157 | -242 | -40 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Sept 2025 |  Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 990.70 |
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 | Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation2 days ago
2 days agoCompletion Of USFDA Inspection6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation10 days ago
10 days agoLetter To Shareholders Regarding Annual ReportAug 28, 2025
Aug 28, 2025General AnnouncementAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 27, 2025
Aug 27, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Aug 26, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Notice Of AGMAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Completion Of USFDA InspectionAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Outcome Of The Board MeetingAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Giving Of Corporate GuaranteeJul 29, 2025
Jul 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2025
Jul 22, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJul 19, 2025
Jul 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ending June 30 2025Jun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 20, 2025
Jun 20, 2025Disclosure Regarding Sale Of Assets Of Clinical Research And Bio-Analytical Studies Site (CR Bio) Of The Company.Jun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Credit RatingMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 28, 2025
May 28, 2025Financial Results For Period Ended March 31 2025May 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 28, 2025
May 28, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
May 26, 2025General AnnouncementMay 25, 2025
May 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
May 19, 2025Change In The Name And Trading SymbolMay 13, 2025
May 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 13, 2025
May 13, 2025Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011May 12, 2025
May 12, 2025Technical Indicators
RSI(14)
Neutral 57.85
ATR(14)
Less Volatile 34.68
STOCH(9,6)
Neutral 71.20
STOCH RSI(14)
Neutral 72.80
MACD(12,26)
Bullish 11.66
ADX(14)
Strong Trend 27.05
UO(9)
Bearish 62.47
ROC(12)
Uptrend And Accelerating 12.50
WillR(14)
Neutral -26.40
Mutual Fund Holdings
Invesco India Smallcap Fund Direct - Growth 
Aditya Birla Sun Life Mid Cap Direct Fund-Growth 
Axis Flexi Cap Fund Direct-Growth 
DSP Top 100 Equity Direct Plan-Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
Bank of India Small Cap Fund Direct-Growth 
Union Large & Midcap Fund Direct - Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
360 ONE Focused Fund Direct-Growth 
Bandhan Business Cycle Fund Direct-Growth 
UTI Healthcare Fund Direct-Growth 
Mirae Asset Small Cap Fund Direct-Growth 
LIC MF Healthcare Fund Direct - Growth 
360 ONE Multi Asset Allocation Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
